Home › Mieloma multiplo › Maryland › Baltimore
Studi clinici su Mieloma multiplo a Baltimore, MD
13 studi su Mieloma multiplo cercano partecipanti presso sedi a Baltimore e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 3
- Johns Hopkins Hospital, Baltimore
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 3
- University of Maryland School of Medicine, Baltimore
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
In reclutamentoFase 3
- Johns Hopkins University School of Medicine JHUSOM, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
In reclutamentoFase 1 iniziale
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
In reclutamentoFase 3
- Johns Hopkins Asthma & Allergy Center, Baltimore
Collection of Tissue Samples for Cancer Research
In reclutamentoStudio osservazionale
- Johns Hopkins University, Baltimore
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
In reclutamentoFase 3
- University of Maryland | Greenebaum Cancer Center, Baltimore
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
In reclutamentoFase 3
- Research Site, Baltimore
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
In reclutamentoFase 1
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
In reclutamentoFase 3
- Greater Baltimore Medical Center, Baltimore
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
In reclutamentoFase 3
- Greenebaum Cancer Center UM of MD, Baltimore
- John Hopkins, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
In reclutamentoFase 1/2
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 1/2
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Studi su Mieloma multiplo in altre città
- New York City, NY60 studi
- Boston, MA42 studi
- Atlanta, GA41 studi
- Houston, TX38 studi
- Durham, NC37 studi
- Nashville, TN32 studi
- Denver, CO27 studi
- Rochester, MN24 studi
- St. Louis, MO24 studi
- Columbus, OH24 studi
- Baldwin Park, CA23 studi
- Chicago, IL22 studi
Altri studi a Baltimore
- Cancro del polmone non a piccole cellule60 studi
- Cancro al seno47 studi
- Cancro alla prostata43 studi
- Cancro ai polmoni40 studi
- Cancro (tutti i tipi)37 studi
- Cancro colorettale31 studi
- Cancro pancreatico31 studi
- Cancro metastatico28 studi
- Obesità25 studi
- Insufficienza cardiaca24 studi
- Cancro della vescica24 studi
- Ictus22 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.